Plus500 does not provide CFD services to residents of the United States. Visit our U.S. website at us.plus500.com.

Markets React to UK Vaccine Approval

FTSE100 (UK100) futures jumped 1.1% yesterday and Pfizer (PFE) climbed as high as 2.3%  to $41.32 during yesterday’s trading following COVID-19 vaccine approval before closing at $40.72.

UK vaccine

Yesterday, the UK’s health agency, the MHRA, announced approval of Pfizer and BioNtech’s request for emergency approval for their COVID-19 vaccine. This makes the UK the first country to have approved any Coronavirus vaccine, which will begin being administered as early as next week.

Currently, there are 800,000 doses on the way to the UK with elderly people and their caretakers slated to be the first to receive this vaccine. This comes on the heels of governments across Europe and some American localities imposing new lockdown restrictions to help curb the spread of the virus. In reaction to this long anticipated COVID vaccine, some shares, commodities, and index futures moved higher during yesterday’s trading.

Vaccine developers saw a boost in share prices, such as Moderna (MRNA), which closed 1.4% higher. Even Astrazeneca (AZN-L), who need to retest their vaccines after inconsistent testing reports, notched 1.2% higher to £7972 per share before closing at £7,926.

Oil Climbs Following Vaccine Approval

Oil futures traded higher yesterday as markets looked beyond the pandemic to an eventual softening of lockdowns, following the vaccine news. Since March of this year, Oil has struggled to return to pre-pandemic valuations. 

American West Texas Intermediate Oil (CL) futures rose 3.5% to a high of $45.88 during yesterday’s trading before closing the day at $44.94. North Sea Brent Crude (EB) futures rose 3.7% to a high of $48.74 during yesterday’s trading, yet closed the day at $47.98. This also pushed British Oil and gas producer, BP (BP-L) to close 4.7% higher during yesterday’s trading.

This vaccine approval indicates a turning point in the fight against the Coronavirus. While it may be some time before full populations can be immunized, leaving traders to speculate on the potential for future market volatility.

Articoli più recenti


Ottieni di più da Plus500

Amplia le tue conoscenze

Approfondisci le tue conoscenze attraverso video, articoli e guide informative con la nostra esauriente Trading Academy.

Scopri il nostro +Insights

Scopri ciò che fa tendenza all'interno e all'esterno di Plus500.


Queste informazioni sono state scritte da Plus500 Ltd. Le informazioni sono fornite solo per scopi generali e non tengono conto di circostanze o obiettivi personali. Prima di agire sulla base di queste informazioni, dovresti valutare se sono adatte alla tua situazione specifica e, se necessario, chiedere un parere professionale. Non viene fornita alcuna dichiarazione o garanzia in merito all'accuratezza o alla completezza di queste informazioni. Non costituisce una consulenza finanziaria, di investimento o di altro tipo su cui fare affidamento. Qualsiasi riferimento ai risultati passati, ai rendimenti storici, alle proiezioni future e alle previsioni statistiche non è garanzia di rendimenti o performance futuri. Plus500 non sarà ritenuta responsabile per qualsiasi uso che possa essere fatto di queste informazioni e per le conseguenze che potrebbero derivare da tale uso. Pertanto, chiunque agisca sulla base di queste informazioni lo fa a propria discrezione. Le informazioni non sono state preparate in base ai requisiti legali che mirano a promuovere l'indipendenza della ricerca in materia di investimenti.

I CFD su criptovalute non sono disponibili ai clienti al dettaglio.

Inizia a fare trading